“TranSenda is pleased to have the opportunity to contribute to the BioMarkers project.” states Bob Webber, TranSenda’s President and CEO, “We are interested in determining how TranSenda’s modular clinical trial products and graphical workflow platform can assist with the challenges of data integration across the drug discovery, preclinical and clinical drug development stages, leading towards eventual application in the field of targeted treatments.”
“For our early purposes, TranSenda and other BioIT Alliance partners will cooperate on creating a virtual proof of concept that would enable us to share data among members of the BioIT Alliance.” said Don Rule, Platform Strategy Advisor at Microsoft Corporation. “This will enable us to determine where the gaps are and make sure that we can provide an integrated solution.”